×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Company: Dopamine Transporter Modulators for Parkinson's Disease
company
617 words
Contents
Dopamine Transporter Modulators for Parkinson's Disease
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Crunchbase
Wikipedia
Related Hypotheses (109)
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat
Score: 0.71
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.70
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
Score: 0.70
Targeted Butyrate Supplementation for Microglial Phenotype M
Score: 0.70
SASP-Mediated Complement Cascade Amplification
Score: 0.70
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.70
Axonal RNA Transport Reconstitution
Score: 0.70
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th
Score: 0.69
Palmitoylation-Targeted BACE1 Trafficking Disruptors
Score: 0.69
Sphingomyelin Synthase Activators for Raft Remodeling
Score: 0.69
Extracellular Matrix Stiffness Modulation
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.69
Pericyte Contractility Reset via Selective PDGFR-β Agonism
Score: 0.68
Context-Dependent CRISPR Activation in Specific Neuronal Sub
Score: 0.68
Flotillin-1 Stabilization Compounds
Score: 0.68
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68
← Prev
pg 3/6
Next →
Related Analyses (30)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Show 25 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · completed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40
AAV-LRRK2 Gene Therapy IND-Enabling Study Design
clinical · proposed · Score: 0.40
Show 25 more
See Also (13)
Striatum
brain · KG edge: expressed_in
Parkinson Basal Ganglia Circuit
circuit · KG edge: loss_affects
NeuRon Therapeutics
company · KG edge: loss_affects
Neurodegeneration
disease · KG edge: loss_affects
acetylcholine
general · KG edge: co_discussed
Amyloid-Related Imaging Abnormalities (ARIA)
entity · KG edge: activates
BDNF Gene
gene · KG edge: regulates
COMT Gene
gene · KG edge: regulates
GPX4 Gene - Glutathione Peroxidase 4
gene · KG edge: regulates
NRF2 Gene
gene · KG edge: activates
SNCA — Alpha-Synuclein
gene · KG edge: loss_affects
Alzheimer Indonesia
institution · KG edge: loss_affects
Levodopa for Parkinson's Disease — Investment Landscape
investment · KG edge: converts_to
Show 8 more
Knowledge Graph (8 edges)
Cellular Senescence
expressed_in
Dopaminergic Neurons
ASK1
causes
Dopaminergic Neuron Degeneration
Dopaminergic Degeneration
contributes_to
Parkinson's Disease
Microglia
causes
Dopaminergic Neurons
CYTOKINES
involved_in
Dopaminergic Neuron Degeneration
Dopaminergic Neurons
involved_in
Parkinson's Disease
35345678
blocks the reuptake of
Dopamine
35345678
blocks reuptake of
Dopamine
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.